Disease/Infection News

RSS

Small financial incentives can improve people’s completion of HBV vaccination, study finds

Small financial incentives, totalling as little as £30, can dramatically increase the likelihood of people who inject drugs completing a course of hepatitis B virus (HBV) vaccination, according to new research published in The Lancet.

10 Apr 2014

University of Montreal scientists discover molecular details of kissing disease virus attacks

University of Montreal researchers have discovered how a component of the Epstein Barr (EBV) virus takes over our cells gene regulating machinery, allowing the virus to replicate itself.

10 Apr 2014

Spero Therapeutics enters into antibiotics partnership with Roche

Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for treatment of bacterial infections, has entered into an antibiotics partnership with Roche.

9 Apr 2014

Forest Laboratories, Almirall receive feedback from FDA regarding fixed dose combination of aclidinium/formoterol

Forest Laboratories, Inc. and Almirall, S.A. today announced that they have recently received feedback from the U.S. Food and Drug Administration (FDA) regarding the fixed dose combination of aclidinium and formoterol.

9 Apr 2014

Scientists seek broad, versatile countermeasures effective against several kinds of viruses, other pathogens

A group of University of Washington scientists is seeking broad, versatile countermeasures effective against several different kinds of viruses and other pathogens. The investigators are part of a national push for faster responses to unexpected infectious agents.

9 Apr 2014

EASL to present online HCV management recommendations at the ILCTM

The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress- (ILC).

9 Apr 2014

Expert guidance highlights strategies to prevent catheter-associated urinary tract infections

New expert guidance highlights strategies for implementing and prioritizing efforts to prevent catheter-associated urinary tract infections (CAUTI) in hospitals.

9 Apr 2014

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")( TOKYO:4587) announced today, in collaboration with The Tokyo Metropolitan Institute of Medical Science ("Tokyo Metropolitan Institute") the discovery and development of a novel macrocyclic peptide inhibitor for the treatment of multiple influenza strains.

8 Apr 2014

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have submitted new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for the investigational products daclatasvir (DCV), an NS5A replication complex inhibitor, and asunaprevir (ASV), a NS3 protease inhibitor.

8 Apr 2014

Antimicrobial agent in personal care products boosts colonization of bacteria inside human noses

An antimicrobial agent found in common household soaps, shampoos and toothpastes may be finding its way inside human noses where it promotes the colonization of Staphylococcus aureus bacteria and could predispose some people to infection.

8 Apr 2014

Research to understand exactly how bleach kills bacteria

Spring cleaning often involves chlorine bleach, which has been used as a disinfectant for hundreds of years. But our bodies have been using bleach's active component, hypochlorous acid, to help clean house for millennia. As part of our natural response to infection, certain types of immune cells produce hypochlorous acid to help kill invading microbes, including bacteria.

8 Apr 2014

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Scientists from INRA and INSERM (France) in collaboration with scientists from McMaster University (Canada) and the Ecole polytechnique fédérale of Zurich (Switzerland) have shown that Elafin, a human protein, plays a key role against the inflammatory reaction typical of celiac disease (gluten intolerance).

8 Apr 2014

Researchers warn that chikungunya virus is poised to invade in the Americas

A team of French and Brazilian researchers warn that chikungunya virus is poised to invade, and become epidemic in the Americas according to research published ahead of print in the Journal of Virology.

8 Apr 2014

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. In early 2012, the combination was approved for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) who have not received previous antiretroviral treatment.

8 Apr 2014

Researchers show that vitamin B3 can slow down progression of mitochondrial disease

The researchers of the University of Helsinki, Finland, and école Polytechnique Fédérale de Lausanne, Switzerland, have shown that vitamin B3 form nicotinamide riboside can slow down the progression of mitochondrial disease, suggesting its potential as a novel therapy approach to adult-onset mitochondrial muscle diseases.

7 Apr 2014

Repellents from Greek herb extracts show potent effects against malaria carrying mosquitoes

Repellents derived from Greek herb extracts show potent effects, as spatial repellents, against malaria carrying mosquitoes, and possibly others.

4 Apr 2014

Researchers develop new eco repellent that stops mosquitoes from attacking humans

This year's World Health Day (April 7th) focuses on vector-borne diseases, like malaria. Malaria still kills more than half a million people every year, mainly children. In the battle against this disease researchers in Switzerland have developed a new eco repellent that stops mosquitoes from attacking humans.

4 Apr 2014

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.

3 Apr 2014

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.

3 Apr 2014

Humans appear to develop immunity against strain-specific Lyme disease that lasts for years

Lyme disease, if not treated promptly with antibiotics, can become a lingering problem for those infected. But a new study led by researchers from the University of Pennsylvania has some brighter news: Once infected with a particular strain of the disease-causing bacteria, humans appear to develop immunity against that strain that can last six to nine years.

3 Apr 2014

Disease/Infection News

Small financial incentives can improve people’s completion of HBV vaccination, study finds

University of Montreal scientists discover molecular details of kissing disease virus attacks

Spero Therapeutics enters into antibiotics partnership with Roche

Forest Laboratories, Almirall receive feedback from FDA regarding fixed dose combination of aclidinium/formoterol

Scientists seek broad, versatile countermeasures effective against several kinds of viruses, other pathogens

EASL to present online HCV management recommendations at the ILCTM

Expert guidance highlights strategies to prevent catheter-associated urinary tract infections

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Antimicrobial agent in personal care products boosts colonization of bacteria inside human noses

Research to understand exactly how bleach kills bacteria

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Researchers warn that chikungunya virus is poised to invade in the Americas

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

Researchers show that vitamin B3 can slow down progression of mitochondrial disease

Repellents from Greek herb extracts show potent effects against malaria carrying mosquitoes

Researchers develop new eco repellent that stops mosquitoes from attacking humans

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Humans appear to develop immunity against strain-specific Lyme disease that lasts for years

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News